Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$883.20 USD

883.20
505,652

-7.48 (-0.84%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $881.43 -1.77 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

EXEL vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

by Zacks Equity Research

Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.

Regeneron (REGN) Reports Next Week: What You Should Expect

by Zacks Equity Research

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power

by Zacks Equity Research

Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

by Zacks Equity Research

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

by Zacks Equity Research

Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

by Zacks Equity Research

The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Why Regeneron (REGN) Could Beat Earnings Estimates Again

by Zacks Equity Research

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

by Zacks Equity Research

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.

EXEL or REGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks

by Zacks Equity Research

Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.

Ekta Bagri headshot

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

by Ekta Bagri

Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA

by Zacks Equity Research

Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.

Sheraz Mian headshot

Top Research Reports for JPMorgan Chase, Merck & SAP

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and SAP SE (SAP).

Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study

by Zacks Equity Research

Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

by Zacks Equity Research

Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.

Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?

by Zacks Equity Research

Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up

by Zacks Equity Research

NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.

Regeneron (REGN) Gets FDA Nod for Praluent Label Extension

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.